Research findings, pricing news, and vendor analysis across the peptide market.
Posts about Semaglutide
Showing 1 to 10 of 10
Semaglutide longevity research now spans aged-mouse survival and human cognition records. See the actual numbers, compare research-vial prices, and check the evidence behind each offer.
Read more →VK2735 maintenance dosing preserved a company-reported 90% of prior weight loss with combined every-other-week regimens and 85% with combined monthly regimens over 12 weeks. Here is how those topline results compare with continued weekly treatment, placebo, and current semaglutide and tirzepatide buying options.
Read more →GLP-1 testosterone research points to modest improvements in men with obesity-related functional hypogonadism, especially when weight and insulin resistance improve. Compare the strongest semaglutide and tirzepatide evidence, current prices, and buyer checks before choosing a product or provider.
Read more →Hormonal shifts after 40 make weight loss harder. GLP-1 medications can help — but the research on women specifically tells a different story than the headlines.
Read more →The current evidence does not show a broad human cancer-risk increase from GLP-1 drugs, and some studies suggest lower risk for obesity-related cancers. This explainer separates thyroid-label warnings, pancreatic-cancer fears, observational signals, and what the data cannot prove.
Read more →New studies show that people who lose weight with GLP-1 medications can be judged more harshly than people who lose weight through diet and exercise. Here is what the stigma research means for disclosure, care-seeking, and how we talk about obesity treatment.
Read more →GLP-1s work without strict dieting — but the research shows that adding protein and resistance training dramatically improves results and prevents muscle loss.
Read more →PCOS affects 1 in 10 women and is driven by insulin resistance. GLP-1 medications target that root cause — and the early research is promising.
Read more →New research from the Technical University of Munich and Harvard Medical School reveals that semaglutide and tirzepatide don't just promote weight loss — they appear to fundamentally reshape the body's metabolic and inflammatory pathways in ways researchers didn't fully anticipate.
Read more →New research from the University of Eastern Finland has found that semaglutide (Ozempic/Wegovy) is associated with significantly reduced rates of depression, anxiety, and substance use disorders — adding to a growing body of evidence that GLP-1 drugs do far more than cause weight loss.
Read more →STOP PIECING IT TOGETHER
We wrote the shortcut: five books, 55 compounds, every claim graded by the strength of the real evidence. No hype, no gatekeeping, and free updates for life whenever the market shifts. Most readers say it replaces months of forum digging.
